Study title: Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of the efficacy and tollerability of budesonide spray aereosol (200 mcg unit dose twice daily) administered via pMDI using the HFA-134a or the CFC propellant in a 12-week treatment period of mild to moderate persistent asthma in pediatric patients comparison with an open-label control group treated with budesonide HFA-134a (200 mcg unit dose twice daily) given with the `jet` spacer device
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Respiratory Tract Diseases | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: BUDESONIDE | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: DM/PR/3307/003/03 | |||||
| EudraCT number: | |||||
| Scope of study: | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |